TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) Operating income 2016–2025
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) annual operating income history from SEC filings — each fiscal year as reported.
$2.2BFY2025 · since FY2016: $2.2B → $2.2B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $2.2B | +811.9% |
| FY2024 | -$303.0M | -170.0% |
| FY2023 | $433.0M | +119.7% |
| FY2022 | -$2.2B | -228.0% |
| FY2021 | $1.7B | +148.0% |
| FY2020 | -$3.6B | -706.3% |
| FY2019 | -$443.0M | +72.9% |
| FY2018 | -$1.6B | +90.6% |
| FY2017 | -$17.5B | -911.7% |
| FY2016 | $2.2B | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TEVA financial trends
TEVA RevenueTEVA Net incomeTEVA Net marginTEVA Gross profitTEVA Gross marginTEVA Operating marginTEVA Operating cash flowTEVA Free cash flowTEVA Capital expendituresTEVA Return on equityTEVA Stock buybacksTEVA Dividends paidTEVA Total assetsTEVA Total liabilitiesTEVA Shareholders’ equityTEVA overview →